Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QQRS | ISIN: US92765F1084 | Ticker-Symbol: RYI
Lang & Schwarz
06.06.25 | 15:45
0,019 Euro
-100,00 % -0,019
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
VIRACTA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
VIRACTA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0080,03015:45

Aktuelle News zur VIRACTA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.02.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 10.02.2025497The following instruments on Boerse Frankfurt do have their last trading day on 10.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 10.02.2025ISIN NameES0105015012 LAR...
► Artikel lesen
07.02.Viracta Therapeutics Terminates Employees & Winds Down Operations2
VIRACTA THERAPEUTICS Aktie jetzt für 0€ handeln
05.02.Viracta Therapeutics to cease operations and seek alternatives5
05.02.Viracta Therapeutics stellt Betrieb ein und sucht nach Alternativen10
05.02.Viracta Therapeutics, Inc.: Viracta Therapeutics Announces Wind Down of Operations241SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers...
► Artikel lesen
04.02.XFRA RYI: AUSSETZUNG/SUSPENSION168DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILVIRACTA THERAP.I.DL-...
► Artikel lesen
03.02.Viracta Therapeutics to be delisted from Nasdaq2
31.01.Viracta Therapeutics, Inc. - 8-K, Current Report11
24.01.Viracta Therapeutics, Inc. - 8-K, Current Report2
17.01.Viracta Therapeutics, Inc. - 8-K, Current Report2
27.12.24Viracta falls on plans to explore strategic options11
27.12.24Viracta Therapeutics Engages In Strategic Alternatives, Closes NAVAL-1 Trial3
26.12.24Viracta Therapeutics, Inc.: Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives249SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers...
► Artikel lesen
26.12.24Viracta Therapeutics, Inc. - 8-K, Current Report1
13.11.24Viracta Therapeutics, Inc.: Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update709- Reprioritized resources to reduce costs and enhance focus on Nana-val's development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report...
► Artikel lesen
18.08.24Biotech Buzz: VIRX Cuts 23% Jobs, FDA Oks New Drug For Hypoparathyroidism, SIGA Down But Not Out1.476LONDON (dpa-AFX) - This week, once again, companies across the biotech sector continued to re-evaluate their pipelines and trim their workforces in a bid to conserve cash and extend their financial...
► Artikel lesen
14.08.24Viracta Therapeutics, Inc.: Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update265- Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val's substantial...
► Artikel lesen
14.08.24Viracta Therapeutics, Inc.: Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan131- New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial further demonstrate Nana-val's substantial...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1